“Best practice” in inflammatory bowel disease: an international survey and audit

Eijk, Ingrid van der; Verheggen, Frank W.S.M.; Rüssel, Maurice G.; Buckley, Martin; Katsanos, K.H.; Munkholm, Pia; Engdahl, Ingemar; Politi, Pierluigi; Odes, Selwyn; Fossen, J B Van; Stockbrügger, Reinhold W.

doi:10.1016/j.ejim.2004.01.016

Cited by 22 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nutritional care includes prevention or treatment of malnutrition and micronutrient deficiencies and, in children, promotion of optimal growth and development. Easy accessibility to a nutritionist or nutritional support team for comprehensive assessment and management has been recommended by several groups, 6 , 21 with the importance of specific knowledge of IBD highlighted in a survey of gastroenterologists. 15 Furthermore, specialists in stoma care have also been cited as important in the MDT.…”

Section: Resultsmentioning

confidence: 99%

“…An international survey of gastroenterologists has recommended continuity of care by the same endoscopist. 21 Other recommendations are that endoscopic and radiology units are available in the same hospital as the IBD unit and that patients should be managed by endoscopists and radiologists with specific training or a special interest in IBD. 6 , 7 An IBD expert pathologist is important in the work-up of IBD patients, particularly for differential diagnosis and special situations inherent to therapy [such as the risk of cytomegalovirus infection reactivation].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.

Louis

Dotan

Ghosh

et al. 2015

ECCOJC

View full text Add to dashboard Cite

Introduction:The best care setting for patients with inflammatory bowel disease [IBD] may be in a dedicated unit. Whereas not all gastroenterology units have the same resources to develop dedicated IBD facilities and services, there are steps that can be taken by any unit to optimise patients’ access to interdisciplinary expert care. A series of pragmatic recommendations relating to IBD unit optimisation have been developed through discussion among a large panel of international experts.Methods:Suggested recommendations were extracted through systematic search of published evidence and structured requests for expert opinion. Physicians [n = 238] identified as IBD specialists by publications or clinical focus on IBD were invited for discussion and recommendation modification [Barcelona, Spain; 2014]. Final recommendations were voted on by the group. Participants also completed an online survey to evaluate their own experience related to IBD units.Results:A total of 60% of attendees completed the survey, with 15% self-classifying their centre as a dedicated IBD unit. Only half of respondents indicated that they had a defined IBD treatment algorithm in place. Key recommendations included the need to develop a multidisciplinary team covering specifically-defined specialist expertise in IBD, to instil processes that facilitate cross-functional communication and to invest in shared care models of IBD management.Conclusions:Optimising the setup of IBD units will require progressive leadership and willingness to challenge the status quo in order to provide better quality of care for our patients. IBD units are an important step towards harmonising care for IBD across Europe and for establishing standards for disease management programmes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.

Louis

Dotan

Ghosh

et al. 2015

ECCOJC

View full text Add to dashboard Cite

show abstract

“…In a recent study van der Eijk et al have shown that perceptions of IBD patients and their treating physicians differed significantly (13). Physicians consider as important aspects the accessibility to care and the information, whereas patients appreciate more the competence of the treating physician, the continuity of care and the cost aspects (13).…”

Section: Introductionmentioning

confidence: 99%

Patients’ perceptions as an indicator of quality of care, in Greek patients with inflammatory bowel disease

Pallis

Κωσταγιόλας

Mouzas

et al. 2009

Scandinavian Caring Sciences

View full text Add to dashboard Cite

show abstract

“…Nonetheless, surveys reveal that patients still feel insufficiently informed and would like greater involvement in their treatment, especially when assessing disease activity, its consequences, and the risks of therapy (Sands et al 2006). It is important to discuss patients’ worries and concerns, not only regarding their physical problems but also their emotional needs, which for some will require psychosocial counseling to improve quality of life (Moser et al 1995; Van Der Eijk et al 2004). Changes in disease activity cause significant psychological distress over time and are closely related to increases and decreases in anxiety and depression scores in IBD patients.…”

Section: Patient-specific Implications (Quality Of Life Satisfactionmentioning

confidence: 99%

Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)

Dinesen¹,

Travis²

2007

International Journal of Nanomedicine

View full text Add to dashboard Cite

A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn’s disease. Crohn’s disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Since inflammatory bowel disease (IBD) represents a state of dysregulated inflammation, drugs that augment the anti-inflammatory response have the potential to downregulate inflammation and thereby hopefully modify the disease. Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has proinflammatory effects in the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown in Phase III trials to achieve and maintain clinical response and remission in Crohn’s disease patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to severely active Crohn’s disease, but it is not yet licensed in Europe or the US. It is not possible to construct an algorithm for treatment, but when compared with infliximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of administration. These two factors may be sufficient to promote it up the pecking order of anti-TNF agents.

show abstract

“Best practice” in inflammatory bowel disease: an international survey and audit

Cited by 22 publications

References 16 publications

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.

Patients’ perceptions as an indicator of quality of care, in Greek patients with inflammatory bowel disease

Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)

Contact Info

Product

Resources

About